AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9864077 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine (serum drug level 6.1+/‐1.3 microg/mL)
Number of subjects: 171
Study 9864077 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 171
Study 9864077 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 171
Study 8471984 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide with low dose alpha-interferon (IFN)
Number of subjects: 34
Study 8471984 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide alone (Control)
Number of subjects: 34
Study 3107374 — intervention group
Group type: EXPERIMENTAL
Intervention: Wet cryoprecipitate
Number of subjects: 5
Study 3107374 — intervention group
Group type: COMPARATOR
Intervention: Lyophilized cryoprecipitate
Number of subjects: 5
Study 3107374 — intervention group
Group type: COMPARATOR
Intervention: Fraction I-O
Number of subjects: 5
Study 30372588 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 210
Study 30372588 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 210
Study 27580688 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 followed by PPSV23 (prime-boost group)
Number of subjects: 64
Study 27580688 — intervention group
Group type: COMPARATOR
Intervention: PPSV23 alone (PPSV23-alone group)
Number of subjects: 64
Study 25525163 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplement (vitamin C, E, zinc, lutein/zeaxanthin, selenium, taurine, Aronia extract, omega-3 free fatty acids)
Number of subjects: 43
Study 25525163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 22849546 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day sequential therapy (5 days of lansoprazole and amoxicillin followed by 5 days of lansoprazole, clarithromycin, and metronidazole)
Number of subjects: 159
Study 22849546 — intervention group
Group type: COMPARATOR
Intervention: Conventional triple therapy (10 days of lansoprazole, amoxicillin, and clarithromycin)
Number of subjects: 159
Study 20152599 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior capsule polishing
Number of subjects: 20
Study 20152599 — intervention group
Group type: COMPARATOR
Intervention: Unpolished eyes (control)
Number of subjects: 20
Study 20152599 — intervention group
Group type: COMPARATOR
Intervention: Clinical comparison of polished vs unpolished eyes
Number of subjects: 20
Study 17432784 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg once daily for 3 days after extraction
Number of subjects: 400
Study 17432784 — intervention group
Group type: COMPARATOR
Intervention: Physiologic saline 3 times daily from 24 hours after extraction for 7 days
Number of subjects: 400
Study 16137195 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsatellite polymorphisms in XRCC1, XRCC3 and XRCC5
Number of subjects: 62
Study 16137195 — intervention group
Group type: EXPERIMENTAL
Intervention: Rare XRCC1 [AC]11 and [AC]21 repeats
Number of subjects: 62
Study 16137195 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsatellite repeat length in XRCC1 and XRCC5
Number of subjects: 62
Study 16137195 — intervention group
Group type: EXPERIMENTAL
Intervention: XRCC3 [AC]16 homozygotes
Number of subjects: 62
Study 11870500 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (800 mg day(-1) orally) + 5-fluorouracil (200 mg day(-1))
Number of subjects: 64
Study 11870500 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil alone
Number of subjects: 64
Study 10447370 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (IB) 200 microg
Number of subjects: 60
Study 10447370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 8949823 — intervention group
Group type: EXPERIMENTAL
Intervention: LS (lateral insertion, sitting withdrawal)
Number of subjects: 88
Study 8949823 — intervention group
Group type: COMPARATOR
Intervention: LL (lateral insertion, flexed lateral withdrawal)
Number of subjects: 88
Study 8949823 — intervention group
Group type: COMPARATOR
Intervention: SL (sitting insertion, lateral withdrawal)
Number of subjects: 88
Study 8949823 — intervention group
Group type: COMPARATOR
Intervention: SS (sitting insertion, sitting withdrawal)
Number of subjects: 88
Study 2024754 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lignocaine 1.5 mg/kg
Number of subjects: 60
Study 2024754 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (control)
Number of subjects: 60
Study 7263877 — intervention group
Group type: EXPERIMENTAL
Intervention: Rational-emotive therapy (RET)
Number of subjects: 148
Study 7263877 — intervention group
Group type: COMPARATOR
Intervention: Attention placebo counseling program (control)
Number of subjects: 148
Study 7263877 — intervention group
Group type: COMPARATOR
Intervention: No-treatment group (control)
Number of subjects: 148
Study 31185613 — intervention group
Group type: EXPERIMENTAL
Intervention: Suicide prevention program
Number of subjects: 0
Study 31185613 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 28183585 — intervention group
Group type: EXPERIMENTAL
Intervention: Oblique view (group O)
Number of subjects: 126
Study 28183585 — intervention group
Group type: COMPARATOR
Intervention: Transverse view (group T)
Number of subjects: 126
Study 28183585 — intervention group
Group type: COMPARATOR
Intervention: Longitudinal view (group L)
Number of subjects: 126
Study 24132814 — intervention group
Group type: EXPERIMENTAL
Intervention: SOMA (somatostatin 300 μg/hour and heparin 70 mIE/kg/min)
Number of subjects: 6
Study 24132814 — intervention group
Group type: COMPARATOR
Intervention: SALINE (saline infusion)
Number of subjects: 6
Study 20682548 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term gemcitabine and paclitaxel chemotherapy (arm A)
Number of subjects: 96
Study 20682548 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged gemcitabine and paclitaxel chemotherapy (arm B)
Number of subjects: 96
Study 19330493 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose manidipine/delapril
Number of subjects: 110
Study 19330493 — intervention group
Group type: COMPARATOR
Intervention: Losartan/hydrochlorothiazide
Number of subjects: 110
Study 17570342 — intervention group
Group type: EXPERIMENTAL
Intervention: Single session of behavioral treatment involving self-exposure instructions
Number of subjects: 0
Study 15297125 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection
Number of subjects: 46
Study 15297125 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy (pulsed ultrasound, deep friction massage, exercise programme)
Number of subjects: 46
Study 15297125 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nonsteroid anti-inflammatory drugs
Number of subjects: 46
Study 15297125 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture, extracorporeal shock wave therapy, manipulation, orthoses, low-energy laser, glycosaminoglycan polysulfate injection, botulinum toxin injection, topical nitric oxide application
Number of subjects: 46
Study 11598479 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium dobesilate for two weeks
Number of subjects: 29
Study 11598479 — intervention group
Group type: COMPARATOR
Intervention: High-fiber diet (Control)
Number of subjects: 29
Study 9505735 — intervention group
Group type: EXPERIMENTAL
Intervention: Bispectral index monitoring (Group 2, n = 28)
Number of subjects: 58
Study 9505735 — intervention group
Group type: COMPARATOR
Intervention: Classical signs of depth of anaesthesia (Group 1, n = 30)
Number of subjects: 58
Study 8838609 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine (20, 40 mg)
Number of subjects: 9
Study 8838609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 2654034 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 0
Study 2654034 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 0
Study 891280 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of fenoterol hydrobromide
Number of subjects: 20
Study 891280 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg of fenoterol hydrobromide
Number of subjects: 20
Study 891280 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of fenoterol hydrobromide
Number of subjects: 20
Study 891280 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 mg of ephedrine
Number of subjects: 20
Study 891280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31840327 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis use (ASSIST)
Number of subjects: 2746
Study 31840327 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol use (AUDIT)
Number of subjects: 2746
Study 30421844 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelesis100
Number of subjects: 0
Study 30421844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27653813 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal extracorporeal circulation circuit (MECC, Maquet)
Number of subjects: 60
Study 27653813 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal circulation circuit optimized (ECC.O, Sorin)
Number of subjects: 60
Study 27653813 — intervention group
Group type: COMPARATOR
Intervention: Conventional extracorporeal circuit (CECC, Maquet)
Number of subjects: 60
Study 26104909 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-session small-group discussion on liver cancer and HBV testing
Number of subjects: 1123
Study 26104909 — intervention group
Group type: COMPARATOR
Intervention: Similar session on physical activity and nutrition (Control)
Number of subjects: 1123
Study 24065259 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced sonography with intravenous administration of 2.4 mL of sulfur hexafluoride
Number of subjects: 25
Study 24065259 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced sonography
Number of subjects: 25
Study 24065259 — intervention group
Group type: COMPARATOR
Intervention: Serologic data
Number of subjects: 25
Study 24065259 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonographic results (judged by RBV)
Number of subjects: 25
Study 24065259 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonography for local (extramedullary myeloma) response
Number of subjects: 25
Study 21332811 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-cellulite cream
Number of subjects: 61
Study 21332811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 18647258 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean model recommended for use in economic evaluation.
Number of subjects: 0
Study 18162022 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 836
Study 15220015 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine camsylate (newly developed formulation)
Number of subjects: 18
Study 15220015 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine besylate (conventional formulation)
Number of subjects: 18
Study 15220015 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 18
Study 11558859 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg
Number of subjects: 432
Study 11558859 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 5 mg
Number of subjects: 432
Study 11558859 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 432
Study 11558859 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 5 mg and 10 mg
Number of subjects: 432
Study 11558859 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (all doses)
Number of subjects: 432
Study 9604858 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated coffee (150 ml)
Number of subjects: 4
Study 9604858 — intervention group
Group type: COMPARATOR
Intervention: Specially treated coffee (150 ml)
Number of subjects: 4
Study 7786108 — intervention group
Group type: EXPERIMENTAL
Intervention: Short duration balloon inflation (3 or 4 successive inflations, each ≤ 1 min, total duration ≤ 3 min)
Number of subjects: 224
Study 7786108 — intervention group
Group type: EXPERIMENTAL
Intervention: Long duration balloon inflation (3 to 5 inflations, each of 4 to 5 minutes, total duration ≥ 12 min)
Number of subjects: 224
Study 7786108 — intervention group
Group type: EXPERIMENTAL
Intervention: Short duration balloon inflation
Number of subjects: 224
Study 7786108 — intervention group
Group type: EXPERIMENTAL
Intervention: Long duration balloon inflation
Number of subjects: 224
Study 3540137 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspergillus fumigatus antigen radioimmunoassay (RIA)
Number of subjects: 79
Study 30829117 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training (RAGT)
Number of subjects: 72
Study 30829117 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (CT)
Number of subjects: 72
Study 29667557 — intervention group
Group type: EXPERIMENTAL
Intervention: M2000 (β-D-mannuronic Acid) 500 mg orally twice daily for 12 weeks
Number of subjects: 10
Study 29667557 — intervention group
Group type: COMPARATOR
Intervention: Non-treated group (control)
Number of subjects: 10
Study 28513786 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite resin (CR) sealants
Number of subjects: 123
Study 28513786 — intervention group
Group type: EXPERIMENTAL
Intervention: Atraumatic Restorative Treatment (ART) sealants
Number of subjects: 123
Study 28513786 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified retention assessment criterion
Number of subjects: 123
Study 28513786 — intervention group
Group type: COMPARATOR
Intervention: Traditional retention assessment criterion
Number of subjects: 123
Study 25646254 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily 4% chlorhexidine umbilical cord wash
Number of subjects: 39679
Study 25646254 — intervention group
Group type: COMPARATOR
Intervention: Dry cord care
Number of subjects: 39679
Study 23617089 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin phosphate (CP) 1.2%‐benzoyl peroxide (BPO) 2.5% gel
Number of subjects: 1755
Study 23617089 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin phosphate (CP) 1.2%
Number of subjects: 1755
Study 23617089 — intervention group
Group type: COMPARATOR
Intervention: Benzoyl peroxide (BPO) 2.5%
Number of subjects: 1755
Study 23617089 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 1755
Study 21722003 — intervention group
Group type: EXPERIMENTAL
Intervention: stage-matched intervention
Number of subjects: 326
Study 21722003 — intervention group
Group type: EXPERIMENTAL
Intervention: stage-mismatched intervention
Number of subjects: 326
Study 21722003 — intervention group
Group type: COMPARATOR
Intervention: control treatment
Number of subjects: 326
Study 19539253 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 2797
Study 19539253 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stent (BMS)
Number of subjects: 2797
Study 19539253 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-target lesion target vessel revascularization (TVR)
Number of subjects: 2797
Study 19539253 — intervention group
Group type: EXPERIMENTAL
Intervention: Other major adverse events (including death, myocardial infarction, and stent thrombosis)
Number of subjects: 2797
Study 16448279 — intervention group
Group type: EXPERIMENTAL
Intervention: Pumice before SEP application
Number of subjects: 30
Study 16448279 — intervention group
Group type: COMPARATOR
Intervention: No pumice before SEP application
Number of subjects: 30
Study 14693012 — intervention group
Group type: EXPERIMENTAL
Intervention: Various drinks intended to alleviate sleepiness
Number of subjects: 38
Study 14693012 — intervention group
Group type: COMPARATOR
Intervention: Nontreatment control conditions
Number of subjects: 38
Study 10775629 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant glycoprotein 160 envelope immunogen derived from a virus of genetic subtype B
Number of subjects: 0
Study 10775629 — intervention group
Group type: EXPERIMENTAL
Intervention: Homologous and heterologous antigens
Number of subjects: 0
Study 10775629 — intervention group
Group type: EXPERIMENTAL
Intervention: Particular immunogen
Number of subjects: 0
Study 9365092 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone
Number of subjects: 50
Study 9365092 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular methylprednisolone
Number of subjects: 50
Study 9365092 — intervention group
Group type: COMPARATOR
Intervention: Both treatment groups (oral prednisolone and intramuscular methylprednisolone)
Number of subjects: 50
Study 9365092 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid tapering
Number of subjects: 50
Study 9365092 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial ESR
Number of subjects: 50
Study 1530019 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (6 gm intravenous bolus)
Number of subjects: 12
Study 1530019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 4059295 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 g triletide
Number of subjects: 30
Study 4059295 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g triletide
Number of subjects: 30
Study 4059295 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 g triletide
Number of subjects: 30
Study 31743933 — intervention group
Group type: EXPERIMENTAL
Intervention: PneumRx endobronchial coil system
Number of subjects: 210
Study 31743933 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-Care Medical Management
Number of subjects: 210
Study 28763309 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual site VTE group
Number of subjects: 165
Study 28763309 — intervention group
Group type: COMPARATOR
Intervention: Unusual site VTE group
Number of subjects: 165
Study 27207923 — intervention group
Group type: EXPERIMENTAL
Intervention: Active repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 40
Study 27207923 — intervention group
Group type: COMPARATOR
Intervention: Sham repetitive transcranial magnetic stimulation
Number of subjects: 40
Study 24946635 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint catgut embedding therapy
Number of subjects: 70
Study 24946635 — intervention group
Group type: COMPARATOR
Intervention: Western medication (tamsulosin hydrochloride 0.2 mg once daily, indometacin 75 mg once daily)
Number of subjects: 70
Study 22325459 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride (1 mg/d)
Number of subjects: 0
Study 22325459 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20849659 — intervention group
Group type: EXPERIMENTAL
Intervention: Multispecies probiotic intervention consisting of Lactobacillus rhamnosus GG, L. rhamnosus Lc705, Propionibacterium freudenreichii ssp. shermanii JS and Bifidobacterium breve Bb99
Number of subjects: 42
Study 20849659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 17544361 — intervention group
Group type: EXPERIMENTAL
Intervention: Control-based coping strategies (distraction and cognitive restructuring)
Number of subjects: 98
Study 17544361 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance-based strategies (experiential acceptance and defusion techniques)
Number of subjects: 98
Study 17544361 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 98
Study 15911734 — intervention group
Group type: COMPARATOR
Intervention: Sinus rhythm control
Number of subjects: 4060
Study 15911734 — intervention group
Group type: COMPARATOR
Intervention: Rate control
Number of subjects: 4060
Study 15911734 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin therapy
Number of subjects: 4060
Study 15911734 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation presence at stroke event
Number of subjects: 4060
Study 15911734 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic stroke
Number of subjects: 4060
Study 15911734 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary intraparenchymal hemorrhage
Number of subjects: 4060
Study 15911734 — intervention group
Group type: EXPERIMENTAL
Intervention: Subdural or subarachnoid hemorrhage
Number of subjects: 4060
Study 11777710 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophobic acrylic IOLs (AcrySof, AR40)
Number of subjects: 180
Study 11777710 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophilic acrylic IOLs (MemoryLens, Hydroview)
Number of subjects: 180
Study 11777710 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone IOLs (CeeOn 920, CeeOn 911A)
Number of subjects: 180
Study 11777710 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophilic acrylic IOLs (Hydroview, MemoryLens)
Number of subjects: 180
Study 11777710 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone IOLs
Number of subjects: 180
Study 11777710 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophobic IOL groups
Number of subjects: 180
Study 11777710 — intervention group
Group type: EXPERIMENTAL
Intervention: Sharp-edged optic IOLs (CeeOn 911A, AcrySof)
Number of subjects: 180
Study 11777710 — intervention group
Group type: EXPERIMENTAL
Intervention: AR40 lens
Number of subjects: 180
Study 11777710 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative cell count at 1 year
Number of subjects: 180
Study 9449392 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential hypertension
Number of subjects: 42
Study 9449392 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 42
Study 9449392 — intervention group
Group type: EXPERIMENTAL
Intervention: Congestive heart failure
Number of subjects: 42
Study 9449392 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 42
Study 7653442 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil (10 mg oral administration)
Number of subjects: 10
Study 7653442 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical to nicorandil)
Number of subjects: 10
Study 2572631 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate 4%
Number of subjects: 56
Study 2572631 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycol-poly-siloxane gel
Number of subjects: 56
Study 2572631 — intervention group
Group type: EXPERIMENTAL
Intervention: Bland liquid soap
Number of subjects: 56
Study 2572631 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitive-skin group
Number of subjects: 56
Study 2572631 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal carriers of MRSA
Number of subjects: 56
Study 2572631 — intervention group
Group type: COMPARATOR
Intervention: Weekly MRSA colonization rate in neonates
Number of subjects: 56